The newly incorporated company ‘Numaferm’ enables plannable biotechnological production of peptides at higher yields and at lower costs. Evonik invests in this biotechnology company as it identifies it as a growth opportunity for its health care and specialty additives segment.
Numaferm has developed a technology platform, which enables plannable biotechnological production of peptides at higher yields and at lower costs.
(Source: Evonik)
Essen/Germany – Through its venture capital unit, Evonik has invested in the start-up ‘Numaferm’ and now holds a minority share in the biotechnology company, which is located in Düsseldorf. The investment was made as part of a seed financing round and also includes investments by high-tech Gründerfonds, the Business Angels and Qiagen co-founders Detlev Riesner and Jürgen Schumacher, as well as the European Investment Fund.
Numaferm has developed a technology platform, which enables plannable biotechnological production of peptides at higher yields and at lower costs. The technology can be used for almost all peptides, and production on an industrial scale becomes possible. As a result, new technical applications for peptides also become realistic for the first time.
Peptides and their applications are highly interesting for Evonik’s growth in the health care and specialty additives segment. Numaferm intends to use the fresh capital to drive forward technological development and get the first products to market maturity.
The new company was founded at the beginning of 2017 as a spin-off of the Institute of Biochemistry. Previously, the project was supported by an Exist research transfer of the German Federal Ministry for Economic Affairs and Energy, among others.
Unfold for details of your consent
Stand vom 23.03.2021
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.